Host: Alex Herrera, MD Guest: Alison J. Moskowitz, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our t

Host: Matthew J. Matasar, MD Guest: Kami Maddocks, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our t

Host: Kami Maddocks, MD Guest: Matthew J. Matasar, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our t

Host: John P. Leonard, MD Guest: Sarah Rutherford, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our t

Host: Sarah Rutherford, MD Guest: John P. Leonard, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our t

Host: John P. Leonard, MD Guest: Sarah Rutherford, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our t

Host: Kami Maddocks, MD Guest: Matthew J. Matasar, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our t

Host: Jason J. Luke, MD, FACP Guest: Tara Mitchell, MD The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Fin

Host: Charles P. Vega, MD Guest: Sharon D. Solomon, MD New treatments are available to manage diabetic macular edema (DME) that have the added benefit of reducing treatment burden. This can level the playing field and benefit patients who ar

Host: Charles P. Vega, MD Guest: Pradeep S. Prasad, MD, MBA Vision loss due to diabetes is preventable, yet minority patients and patients of low socioeconomic status remain at a disproportionate risk of poor outcomes. Find out what Dr. Prad